Cosmo Bio CoTSE:3386 -0.55%73 Net Margin % is 1.62% as of Dec. 2025, which is 54% below its 10-year median of 3.50. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,246.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 60.78% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cosmo Bio Co's Net Income for the
six
months ended in Dec. 2025 was 円87 Mil. Cosmo Bio Co's Revenue for the
six
months ended in Dec. 2025 was 円5,364 Mil. Therefore, Cosmo Bio Co's net margin for the quarter that ended in Dec. 2025 was 1.62%.
The historical rank and industry rank for Cosmo Bio Co's Net Margin % or its related term are showing as below:
TSE:3386'
s Net Margin % Range Over the Past 10 Years
Min: 2.61 Med: 3.5 Max: 8.33
Current: 3.13
TSE:3386's Net Margin % is ranked better than 60.78% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.56
vs TSE:3386: 3.13
Cosmo Bio Co (TSE:3386) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cosmo Bio Co Net Margin % Related Terms
Cosmo Bio Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a Net Margin % of 1.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Cosmo Bio Co and its competitors. This is 54% below median its historical median of 3.50. Over the past decade, Cosmo Bio Co's Net Margin % has ranged from 2.61 to 8.33. According to the industry distribution chart, Cosmo Bio Co ranks #80 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 39.2%.
Is Cosmo Bio Co's Net Margin % too high?
Cosmo Bio Co's current Net Margin % of 1.62% is 54% below median its 10-year median of 3.50. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 8.33. Based on the distribution chart, Cosmo Bio Co ranks #80 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #80 out of 204 companies for Net Margin %. This puts Cosmo Bio Co in the upper half of its industry. Historically, Cosmo Bio Co's own Net Margin % has ranged from 2.61 to 8.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cosmo Bio Co and its competitors. Cosmo Bio Co's current Net Margin % is 1.62%, which is 54% below median its own 10-year median of 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,246.90, compared to a current price of 円1,262.00 — trading 1.2% above its estimated fair value. The current Net Margin % is 1.62%, which is 54% below median its 10-year median of 3.50. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current Net Margin % is 1.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,262.00 is trading 1.2% above its estimated GF Value™ of 円1,246.90.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
Net Margin %: 1.62% (54% below median its 10-year median of 3.50)
GF Value™: 円1,246.90 vs. price of 円1,262.00 (1.2% above fair value)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
